leading glp-1 treatments for diabetes 2025 Pipeline Update: August - Prime Therapeutics Puerto Rico leads U.S. growth

Kefurt, R

Although experimental studies suggest potential pancreatic harm from GLP-1 RAs, robust clinical evidence demonstrates that these drugs do not increase the incidence of pancreatitis or pancreatic cancer in diverse human populations

Average results: In a major 2021 NEJM study, people using semaglutide lost around 15% of their weight in just over a year, roughly three times more than those relying only on diet and exercise

Together, we will create a treatment plan that works for you, including microdosing and alternative dosing strategies, to optimize GLP-1 use for patients beyond weight loss and diabetes

Theyre not licensed nationallythey employ providers with licenses in multiple states and match you to someone licensed where you are

Many people, particularly those with PCOS or metabolic syndrome, find that a combination approach addresses different aspects of their health